RSCI (Redwood Scientific Technologies) Long-Term Debt: $0.00 Mil (As of Dec. 2023)


What is Redwood Scientific Technologies Long-Term Debt?

Redwood Scientific Technologies RSCI Long-Term Debt is $0.00 Mil as of Dec. 2023.

Redwood Scientific Technologies's Long-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.

Redwood Scientific Technologies  (OTCPK:RSCI) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Redwood Scientific Technologies Long-Term Debt Related Terms

Redwood Scientific Technologies Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Redwood Scientific Technologies's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redwood Scientific Technologies Long-Term Debt Chart

Redwood Scientific Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Long-Term Debt
0.00 0.00 0.00 0.00

Redwood Scientific Technologies Semi-Annual Data
Dec20 Dec21 Dec22 Dec23
Long-Term Debt 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Redwood Scientific Technologies (RSCI) has a Long-Term Debt of $0.00 Mil as of Dec. 2023.
Is Redwood Scientific Technologies' Long-Term Debt too high?
Redwood Scientific Technologies' current Long-Term Debt is $0.00 Mil.
How does Redwood Scientific Technologies' Long-Term Debt compare to RAPH and FLGC?
Redwood Scientific Technologies' Long-Term Debt of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Redwood Scientific Technologies's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redwood Scientific Technologies stock overvalued right now?
Redwood Scientific Technologies (RSCI) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Redwood Scientific Technologies (RSCI), the current Long-Term Debt is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Redwood Scientific Technologies Business Description

Address 418 Broadway, STE 4872, Albany, NY, USA, 12207
Redwood Scientific Technologies Inc is a pharmaceutical delivery company that develops, operates, and markets over-the-counter products in a sublingual oral thin film strip. RSCI has begun clinical trials on two new products to market for stopping the addiction to nicotine.